Linda Yang1, Jocelyn Shan1, Leonard Shan1, Akshat Saxena1, Lourens Bester1, David L Morris1. 1. 1 Melbourne Medical School, The University of Melbourne, Victoria, Australia ; 2 Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia ; 3 Department of Surgery, St George Hospital, Kogarah, New South Wales, Australia ; 4 Department of Radiology, School of Medicine, University of Notre Dame, Darlinghurst, New South Wales, Australia.
Abstract
BACKGROUND: Unresectable intrahepatic cholangiocarcinoma (ICC) portends a poor prognosis despite standard systemic treatments which confer minimal survival benefits and significant adverse effects. This study aimed to assess clinical outcomes, complications and prognostic factors of TAE therapies using chemotherapeutic agents or radiation. METHODS: A literature search and article acquisition was conducted on PubMed (MEDLINE), OVID (MEDLINE) and EBSCOhost (EMBASE). Original articles published after January 2000 on trans-arterial therapies for unresectable ICC were selected using strict eligibility criteria. Radiological response, overall survival, progression-free survival, safety profile, and prognostic factors for overall survival were assessed. Quality appraisal and data tabulation were performed using pre-determined forms. Results were synthesized by narrative review and quantitative analysis. RESULTS: Twenty articles were included (n=929 patients). Thirty three percent of patients presented with extrahepatic metastases. After treatment, the average rate of complete and partial radiological response was 10% and 22.2%, respectively. Overall median survival time was 12.4 months with a median 30-day mortality and 1-year survival rate of 0.6% and 53%, respectively. Acute treatment toxicity (within 30 days) was reported in 34.9% of patients, of which 64.3% were mild to moderate in severity. The most common clinical toxicities were abdominal pain, nausea and vomiting, and fatigue. Multiplicity, localization and vascularity of the tumor may predict worse overall survival. CONCLUSIONS: Trans-arterial therapies are safe and effective treatment options which should be considered routinely for unresectable ICC. Consistent and standardized methodology and data collection is required to facilitate a meta-analysis. Randomized controlled trials will be valuable in the future.
BACKGROUND: Unresectable intrahepatic cholangiocarcinoma (ICC) portends a poor prognosis despite standard systemic treatments which confer minimal survival benefits and significant adverse effects. This study aimed to assess clinical outcomes, complications and prognostic factors of TAE therapies using chemotherapeutic agents or radiation. METHODS: A literature search and article acquisition was conducted on PubMed (MEDLINE), OVID (MEDLINE) and EBSCOhost (EMBASE). Original articles published after January 2000 on trans-arterial therapies for unresectable ICC were selected using strict eligibility criteria. Radiological response, overall survival, progression-free survival, safety profile, and prognostic factors for overall survival were assessed. Quality appraisal and data tabulation were performed using pre-determined forms. Results were synthesized by narrative review and quantitative analysis. RESULTS: Twenty articles were included (n=929 patients). Thirty three percent of patients presented with extrahepatic metastases. After treatment, the average rate of complete and partial radiological response was 10% and 22.2%, respectively. Overall median survival time was 12.4 months with a median 30-day mortality and 1-year survival rate of 0.6% and 53%, respectively. Acute treatment toxicity (within 30 days) was reported in 34.9% of patients, of which 64.3% were mild to moderate in severity. The most common clinical toxicities were abdominal pain, nausea and vomiting, and fatigue. Multiplicity, localization and vascularity of the tumor may predict worse overall survival. CONCLUSIONS: Trans-arterial therapies are safe and effective treatment options which should be considered routinely for unresectable ICC. Consistent and standardized methodology and data collection is required to facilitate a meta-analysis. Randomized controlled trials will be valuable in the future.
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: U Scheuermann; J M Kaths; M Heise; M B Pitton; A Weinmann; M Hoppe-Lotichius; G Otto Journal: Eur J Surg Oncol Date: 2013-04-20 Impact factor: 4.424
Authors: Charles E Ray; Anthony Edwards; Mitchell T Smith; Stephen Leong; Kimi Kondo; Matthew Gipson; Paul J Rochon; Rajan Gupta; Wells Messersmith; Tom Purcell; Janette Durham Journal: J Vasc Interv Radiol Date: 2013-05-28 Impact factor: 3.464
Authors: S Herber; G Otto; J Schneider; N Manzl; I Kummer; S Kanzler; A Schuchmann; J Thies; C Düber; M Pitton Journal: Cardiovasc Intervent Radiol Date: 2007-05-17 Impact factor: 2.740
Authors: Guido Poggi; A Amatu; B Montagna; P Quaretti; C Minoia; C Sottani; L Villani; B Tagliaferri; F Sottotetti; O Rossi; E Pozzi; F Zappoli; A Riccardi; G Bernardo Journal: Cardiovasc Intervent Radiol Date: 2009-11 Impact factor: 2.740
Authors: Zhongzhi Jia; Ricardo Paz-Fumagalli; Gregory Frey; David M Sella; J Mark McKinney; Weiping Wang Journal: J Cancer Res Clin Oncol Date: 2016-11-08 Impact factor: 4.553
Authors: Jenson Ma; Juan Martin Gimenez; Tyler Sandow; Daniel Devun; David Kirsch; Paul Gulotta; Patrick Gilbert; Dennis Kay Journal: Ochsner J Date: 2017